Triple NRTIs versus Efavirenz + 2-3 NRTIs

ACTG 5095 Trial
# Triple NRTIs versus Efavirenz + 2-3 NRTIs

**ACTG 5095: Study Design**

## Study Design: ACTG 5095

| **Background** | Randomized, double-blind, placebo-controlled, phase 3 trial comparing 3 protease inhibitor-sparing antiretroviral therapy regimens in antiretroviral-naïve patients |
| **Inclusion Criteria (n = 1147)** | - Age ≥18 years  
- Antiretroviral-naïve  
- HIV RNA ≥400 copies/mL |
| **Treatment Arms** | - Triple NRTI: ABC-3TC-ZDV  
- Combined Efavirenz: ZDV-3TC + Efavirenz*  
- Combined Efavirenz: ABC-3TC-ZDV + Efavirenz* |

*Efavirenz arms combined for analysis

**Triple NRTI Group**

ABC-3TC-ZDV  
(n = 382)

**Combined Efavirenz Group**

- Efavirenz + ZDV-3TC  
- Efavirenz + ABC-3TC-ZDV  
(n = 765)

---

Triple NRTIs versus Efavirenz + 2-3 NRTIs

ACTG 5095: Results

Week 48: Virologic Failure

*Virologic failure = two successive HIV-1 RNA values ≥200 copies/mL ≥16 weeks after randomization

Triple NRTIs versus Efavirenz + 2-3 NRTIs

ACTG 5095: Results

Week 48: Virologic Response

Conclusions: “In this trial of the initial treatment of HIV-1 infection, the triple-nucleoside combination of abacavir, zidovudine, and lamivudine was virologically inferior to a regimen containing efavirenz and two or three nucleosides.”
Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

*The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.*